Combined Pharmaceutical formulation comprising amlodipine and losartan rosuvastatin

摘要

Claim 1: a combined Pharmaceutical formulation comprising: (1) a First, Discrete part comprising Amlodipine or one of its pharmaceutically acceptable salts,Rosuvastatin or one of its pharmaceutically acceptable Salts and a pharmaceutically acceptable Additive; and (2) a second part comprising Discrete Losartan or one of its Salts pharmaceutically ACEptables and a pharmaceutically acceptable Additive, where the discrete parts are physically separated.Claim 2: the combined Pharmaceutical formulation of the claim 1Where the combination formulation is presented in the form of a Bilayer Tablet which comprises: (1) a First Layer comprising Amlodipine or one of its pharmaceutically acceptable salts,Rosuvastatin or one of its pharmaceutically acceptable Salts and a pharmaceutically acceptable Additive; and (2) a second layer comprising Losartan or one of its pharmaceutically acceptable Salts andA pharmaceutically acceptable Additive.Claim 8: the formulation of Fixed Dose combination of claim 7, wherein the amount of Amlodipine or one of its pharmaceutically acceptable salts,Converted into the form of Amlodipine Free Base, is 5 to 10 mg.Claim 9: fixed dose Combination formulation of claim 7, where the amount of Rosuvastatin or one of its pharmaceutically acceptable salts,Converted into the Free Base form of Rosuvastatin is 10 to 20 mg.Claim: The 10 fixed dose Combination formulation of claim 7, where the amount of Losartan or one of its pharmaceutically acceptable salts,Converted into the Free Base form of Losartan is 45 to 100 mg.Claim 11: a method for preparing a Pharmaceutical formulation combined, which comprises the steps of: a) mixing Amlodipine or one of its pharmaceutically acceptable salts,Rosuvastatin or one of its pharmaceutically acceptable Salts and Pharmaceutical Additive; (b) Mix Losartan or one of its pharmaceutically acceptable Salts and their salts with pharmaceuticallyDifficult to accept; and (c) carry a discrete part prepared in Step a) and a discrete part prepared in STEP (b) in a formulation, where the discrete parts are physically separated.